Renogen

Recombinant human erythropoietin α

Anemia caused by renal insufficiency in patients w/ chronic renal failure w/ or w/o hemodialysis; non-myeloid malignancy chemotherapy or other factors of cancer patients eg, Fe or folate deficiency, hemolysis or intestinal tract bleeding.

Treatment Patients w/ hemodialysis Initially 150 IU/kg/wk. W/ non-hemodialysis Initially 100 IU/kg/wk. Increased hematocrit by <0.5% vol May increase dose to 15-30 IU/kg after 4 wk. Max: Not >30 IU/kg/wk. Maintenance Baseline Hb ≥3g/dL 25 U/kg/dose, Hb ≥2-<3 g/dL 20 U/kg/dose, Hb >1-<2 g/dL at 12 wk dose increase 15 U/kg/dose.

Hypersensitivity to Renogen or other erythropoietin prep. Patients w/ uncontrolled severe HTN; concurrent infection. Patient who develop pure red cell aplasia following treatment w/ any erythropoietin should not receive epoetinum-α or any erythropoietin.

Closely monitor & control BP. Sudden stabbing migraine-like headache. Discontinue therapy if anti-erythropoietin, Ab-mediated PRCA is suspected; BP cannot be controlled. Patients w/ epilepsy, history of seizures, or medical conditions associated w/ a predisposition to seizure activity eg, CNS infections & brain metastases; underlying haematologic diseases; porphyria; cancer. Increased incidence of thrombotic vascular events. Closely monitor Hb conc. Platelet count should be regularly monitored during 1st 8 wk of therapy. Other causes of anaemia should be evaluated & treated prior to initiation of therapy & before decision to increase dose. Discontinue if a severe cutaneous reaction eg, SJS or TEN is suspected. HIV-infected patients. Adult surgery patients in an autologous pre-donation programme & adult perisurgery patients w/o autologous blood donation. Not recommended in perisurgery patients w/ a baseline Hb of >13 g/dL. Chronic liver & renal failure. Pregnancy & lactation.

Dose-dependent BP increase, diarrhoea, nausea, vomiting, pyrexia, headache, flu-like illness, hypersensitivity reactions, hypertensive crisis w/ encephalopathy-like symptoms & seizures, thrombotic vascular events.

Haematopoietic Agents

B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.

G